Immuneering Corporation announced that it entered into an agreement to expand its existing relationship with Bristol-Myers Squibb for the use of Immuneering's proprietary computational biology methods to identify biological insights that may facilitate discovery and development of medicines. Immuneering's team of MIT-trained PhDs will perform advanced analyses on data from Bristol-Myers Squibb to derive new biological insights. Immuneering uses internally developed proprietary algorithms in combination with software licensed from leading research institutions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.17 USD | -6.40% | -12.69% | -84.08% |
07-01 | Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell 3000E Value Index | CI |
07-01 | Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell 2000 Value Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-84.08% | 34.69M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+46.00% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- IMRX Stock
- News Immuneering Corporation
- Immuneering Corporation Expands Alliance with Bristol-Myers Squibb